The University of Montana, in collaboration with Missoula-based biotech company Inimmune Corporation, has taken a significant step forward in the development of a cancer treatment compound. After receiving grant funding from the National Institutes of Health and multiple years of research, this compound is advancing to human clinical trials in Australia.

Jay Evans, a researcher from the University of Montana, explained that the path from university research to clinical trials is often challenging but rewarding. “Research really is a grind. It’s slow, it’s hard, there’s a lot of failures. But those successes when they happen… Those are rewarding and you see the potential is for things that you are working on to help people,” he said.